[1] |
YE Pei, ZHANG Hewei, LYU Qiang, YE Xiaofei, XU Jinfang, GUO Xiaojing.
Safety of sugammadex for reversal of neuromuscular block based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 321-325.
|
[2] |
HAO Xiaohui, ZHANG Ping, WU Lulu, WANG Lihua.
Mining and analysis of ixazomib citrate capsules safety signals based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1427-1431.
|
[3] |
REN Yuqin, LI Xin, YU Min, SU Yuwen.
Safety evaluation and comparative analysis of rituximab and adalimumab based on openFDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 752-756.
|
[4] |
ZHANG Chi.
Data mining of adverse drug events of alirocumab from openFDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 684-691.
|
[5] |
CUI Xiangli, ZHANG Zhiqi, SUN Liying, GUO Mingxing, ZENG Zhigui, XU Wanyi.
Leflunomide-induced hepatotoxicity: data analysis based on the FDA adverse event reporting system
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 426-431.
|
[6] |
ZHAO Xiaohong, GUO Mingxing, WANG Xiaojian, LIN Jianrui, CUI Xiangli.
Risk signal mining related to lenvatinib based on the US FDA adverse event reporting system
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1233-1237.
|
[7] |
SHA Mingquan, LI Nannan, XIA Wenjing, WEI Qun, WEN Baoshu.
Research and reflection on regulatory science developments of U.S. FDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1055-1059.
|
[8] |
LIU Jing, YE Guoju, WANG Qiming, LIU Wei, ZHAO Dafang, SUN Jun, LI Guoliang, WANG Xinmin, LI Ming.
Detection of report signals of adverse drug reactions by fuzzy BCPNN
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1113-1117.
|
[9] |
LING Tao, XU Ruijuan, GE Weihong.
Comparison Analysis of Adverse Drug Reactions of Rivaroxaban and Apixaban Based on OpenFDA
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 780-783.
|
[10] |
LI Jiangfan, HU Ye, PANG Hongxian, ZHAO Dan, LI Xinru, WANG Xuhong.
Comparative Analysis of Adverse Drug Reactions of Evolocumab and Alirocumab Based on OpenFDA
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 965-968.
|
[11] |
WEI Fuqian, ZHANG Wei, YANG Yue.
Drug Risk Communication between Drug Regulatory Agencies and the Public
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 949-952.
|
[12] |
WEI Fuqian, ZHANG Wei, YANG Yue.
Implementation of US FDA's Drug Risk Evaluation and Mitigation Strategies
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 871-876.
|
[13] |
WANG Linlin, YANG Yue, WANG Shuling.
Application of the US FDA Sentinel System and Enlightenment
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(2): 81-87.
|
[14] |
BAO Cheng-cheng, WANG Hong-wei, YANG Yue.
Consideration on Implementation and Reference Through FDA Risk Evaluation and Mitigation Strategy
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(5): 283-288.
|
[15] |
SHI Wen-hui, CHEN Ying, YAO Jie, SUN Zhi-ming, XU Hao-qin.
Study on Drospirenone and Ethinylestradiol Tablets Using FDA Public Data Program
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(9): 552-555.
|